



SWOG PER-CASE FUNDING FOR S0802

A Randomized Phase II Trial of Weekly Topotecan With or Without AVE0005 (Aflibercept, MSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

FUNDING	AMOUNT/Patient
Federal Funds - Treatment study funds ¹	\$2,000
Federal Funds - Specimen Submission ²	\$500
Total Potential Study Funds	\$2,500

1. Non-CCOPs receive federal funds through their cooperative group. CCOPs receive 1.0 treatment credits instead of direct payment of federal funds.
2. Non-CCOPs and CCOPs will receive federal funds through their cooperative group to help offset costs for specimen submissions as outlined in Section 15.0 of the protocol. Payment will be based on the first submission of data to the SpecTrac system.

Note: Total per case study funds reflects the maximum potential reimbursement amount to institutions

For Medical Questions

Contact:
 Jeffrey W. Allen, M.D.
 Study Chair
 Phone: 901-725-1785
jalien@utcancer.com

For Protocol Questions

Contact:
protocols@swog.org

For Eligibility/Data Questions

Contact:
LungQuestion@crab.org

For Funding Questions

Contact:
 Joy Nickert
 Financial Coordinator
 Phone: 734-998-7174
reillyjl@umich.edu

Revised: 3-24-2011 to reflect Tier II funding for specimen submission: \$500 instead of \$250

